Prima BioMed (ASX:PRR) has announced the granting of patent number 5908210 entitled “Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response” by the Japanese Patent Office.
Prima BioMed is a clinical stage immuno-oncology company, currently in product collaborations with Novartis and GSK, that is chaired by Lucy Turnbull.
This patent relates to Prima’s IMP321 and its use either alone, or in combination, for immunotherapeutic or chemotherapeutic purposes to induce an increase in circulating monocyte numbers in order to protect against cancer.
"This patent will therefore support the use of IMP321 as it is being used in Prima’s AIPAC trial in metastatic breast cancer," said the company.
Patent expiry is expected to be 3rd of October 2028.